D. Heng, J. Wells, B. Rini, B. Beuselinck, J. Lee et al., Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, European Urology, vol.66, issue.4, pp.704-714, 2014.
DOI : 10.1016/j.eururo.2014.05.034

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, and D. Sargent, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

H. Choi, C. Charnsangavej, S. Faria, H. Macapinlac, M. Burgess et al., Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria, Journal of Clinical Oncology, vol.25, issue.13, pp.1753-59, 2007.
DOI : 10.1200/JCO.2006.07.3049

R. Benjamin, H. Choi, and H. Macapinlac, We Should Desist Using RECIST, at Least in GIST, Journal of Clinical Oncology, vol.25, issue.13, pp.1760-1764, 2007.
DOI : 10.1200/JCO.2006.07.3411

B. Ljungberg, S. Campbell, H. Cho, D. Jacqmin, J. Lee et al., The Epidemiology of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.615-621, 2011.
DOI : 10.1016/j.eururo.2011.06.049

X. Rébillard, P. Grosclaude, T. Lebret, J. Patard, C. Pfister et al., Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2010, Progr??s en Urologie, vol.20, issue.4, pp.211-214, 2010.
DOI : 10.1016/S1166-7087(10)70041-5

S. Weikert, H. Boeing, T. Pischon, C. Weikert, A. Olsen et al., Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition, American Journal of Epidemiology, vol.167, issue.4, pp.438-446, 2008.
DOI : 10.1093/aje/kwm321

J. Mclaughlin, P. Lindblad, A. Mellemgaard, M. Mccredie, J. Mandel et al., International renal-cell cancer study. I. Tobacco use, International Journal of Cancer, vol.77, issue.2, pp.194-202, 1995.
DOI : 10.1002/ijc.2910600211

A. Pantuck, A. Zisman, M. Rauch, and A. Belldegrun, Incidental renal tumors, Urology, vol.56, issue.2, pp.190-196, 2000.
DOI : 10.1016/S0090-4295(00)00655-5

M. Nguyen and I. Gill, Effect of Renal Cancer Size on the Prevalence of Metastasis at Diagnosis and Mortality, The Journal of Urology, vol.181, issue.3, pp.1020-1027, 2009.
DOI : 10.1016/j.juro.2008.11.023

S. Benadiba, RENAL nephrometry score : évaluation de la reproductibilité interobservateur entre radiologue et urologue et implication clinique, Thèse pour le diplôme de docteur en médecine, p.66, 2013.

E. D. Leibovich, J. C. Kwon, M. L. Cheville, and . Blute, Radical Nephrectomy for pT1a Renal Masses May be Associated with Decreased Overall Survival Compared with Partial Nephrectomy, The Journal of Urology, vol.179, issue.2, pp.468-73, 2008.

M. Crépel, C. Jeldres, P. Perrotte, U. Capitanio, H. Isbarn et al., Nephron-sparing Surgery Is Equally Effective to Radical Nephrectomy for T1BN0M0 Renal Cell Carcinoma: A Population-based Assessment, Urology, vol.75, issue.2, pp.271-75, 2010.
DOI : 10.1016/j.urology.2009.04.098

H. Van-poppel, D. Pozzo, L. Albrecht, W. Matveev, V. Bono et al., A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma, European Urology, vol.59, issue.4, pp.543-552, 2011.
DOI : 10.1016/j.eururo.2010.12.013

J. R. Colombo, G. P. Haber, J. E. Jelovsek, B. Lane, A. C. Novick et al., Seven Years After Laparoscopic Radical Nephrectomy: Oncologic and Renal Functional Outcomes, Urology, vol.71, issue.6, pp.1149-1154, 2008.
DOI : 10.1016/j.urology.2007.11.081

J. Nayak, P. Patel, and J. Bjazevic, Clinical outcomes following laparoscopic management of pT3 renal masses: A large, multi-institutional cohort, Canadian Urological Association Journal, vol.9, issue.11-12, pp.11-12397, 2015.
DOI : 10.5489/cuaj.2848

C. J. Weight, J. H. Kaouk, N. J. Hegarty, E. M. Remer, C. M. O-'malley et al., Correlation of Radiographic Imaging and Histopathology Following Cryoablation and Radio Frequency Ablation for Renal Tumors, The Journal of Urology, vol.179, issue.4, pp.1277-1281, 2008.
DOI : 10.1016/j.juro.2007.11.075

S. Chawla, P. Crispen, A. Hanlon, R. Greenberg, D. Chen et al., The Natural History of Observed Enhancing Renal Masses: Meta-Analysis and Review of the World Literature, The Journal of Urology, vol.175, issue.2, pp.425-431, 2006.
DOI : 10.1016/S0022-5347(05)00148-5

J. Gnarra, K. Tory, Y. Weng, L. Schmidt, M. Wei et al., Mutations of the VHL tumour suppressor gene in renal carcinoma, Nature Genetics, vol.88, issue.1, pp.85-90, 1994.
DOI : 10.1038/ng0594-85

N. Cornu, M. Rouprêt, K. Bensalah, S. Oudard, and J. Patard, Les anti-angiog??niques : de nouveaux standards th??rapeutiques dans le cancer du rein m??tastatique, Progr??s en Urologie, vol.18, issue.4, pp.69-76, 2008.
DOI : 10.1016/S1166-7087(08)73665-0

T. J. Abrams, L. Lee, and L. Murray, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol Cancer Ther, vol.2, pp.471-478, 2003.

R. Motzer, B. Rini, and R. Bukowski, Sunitinib in Patients With Metastatic Renal Cell Carcinoma, JAMA, vol.295, issue.21, pp.2516-2524, 2006.
DOI : 10.1001/jama.295.21.2516

C. Escudier, C. A. Dromain, S. Cuenod, and . Oudard, Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib

K. M. Krajewski, M. Guo, A. D. Van-den-abbeele, J. Yap, N. Ramaiya et al., Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor???Targeted Therapy in Patients With Advanced Renal Cell Carcinoma, European Urology, vol.59, issue.5, pp.59-856, 2011.
DOI : 10.1016/j.eururo.2011.01.038

S. Oudard, R. Thiam, L. S. Fournier, J. Medioni, M. Lamuraglia et al., Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study, European Journal of Cancer, vol.48, issue.10, pp.48-1512, 2012.
DOI : 10.1016/j.ejca.2012.01.027

P. D. Nathan, A. Vinayan, D. Stott, J. Juttla, and V. Goh, CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies, Cancer Biology & Therapy, vol.9, issue.1, pp.15-19, 2010.
DOI : 10.4161/cbt.9.1.10340

A. D. Smith, M. L. Lieber, and S. N. Shah, Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT, American Journal of Roentgenology, vol.194, issue.1, pp.157-165, 2010.
DOI : 10.2214/AJR.09.2941

A. D. Smith, S. N. Shah, B. I. Rini, M. L. Lieber, and E. M. Remer, Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy, American Journal of Roentgenology, vol.194, issue.6, pp.1470-1478, 2010.
DOI : 10.2214/AJR.09.3456

F. Kunstlinger, Échographie de contraste des tumeurs hépatiques. EMC ? Radiologie et imagerie médicale : Abdominale -Digestive, pp.1-18, 2011.
DOI : 10.1016/s1879-8527(11)72859-3

N. Lassau, A. Brule, L. Chami, B. Benatsou, P. Peronneau et al., ??valuation pr??coce des traitements anti-angiog??niques par ??chographie dynamique de contraste, Journal de Radiologie, vol.89, issue.5, pp.549-555, 2008.
DOI : 10.1016/S0221-0363(08)71480-X

C. Asselin, N. Lassau, and J. Guinebretière, The in vivo murineiterleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of tumour blood vessel formation monitored by Doppler unltrasonography, Gene Therapy

B. Escudier, N. Lassau, and D. Couanet, Phase II trial of thalidomide in renal-cell carcinoma, Annals of Oncology, vol.13, issue.7, pp.1029-1064, 2002.
DOI : 10.1093/annonc/mdf213

M. Lamuraglia, B. Escudier, and L. Chami, To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound, European Journal of Cancer, vol.42, issue.15, pp.2472-2481, 2006.
DOI : 10.1016/j.ejca.2006.04.023

B. Escudier, N. Lassau, and E. Angevin, Phase I Trial of Sorafenib in Combination with IFN ??-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma, Clinical Cancer Research, vol.13, issue.6, pp.1801-1809, 2007.
DOI : 10.1158/1078-0432.CCR-06-1432

D. Giorgi, U. Aliberti, C. Benea, G. Conti, M. Marangolo et al., Effect of Angiosonography to Monitor Response During Imatinib Treatment in Patients with Metastatic Gastrointestinal Stromal Tumors, Clinical Cancer Research, vol.11, issue.17, pp.6171-6176, 2005.
DOI : 10.1158/1078-0432.CCR-04-2046

N. Lassau, L. Chapotot, B. Benatsou, V. Vilgrain, M. Kind et al., Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies, Investigative Radiology, vol.47, issue.12, pp.711-717, 2012.
DOI : 10.1097/RLI.0b013e31826dc255

N. Lassau, J. Bonastre, and M. Kind, Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors, Investigative Radiology, vol.49, issue.12, pp.794-800, 2014.
DOI : 10.1097/RLI.0000000000000085

. Cuenod, Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT, Radiology, vol.2562, pp.511-518, 2010.

C. De-bazelaire, R. Calmon, I. Thomassin, C. Brunon, A. S. Hamy et al., Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study, BMC Cancer, vol.257, issue.1, pp.11-361, 2011.
DOI : 10.1148/radiol.10092021

URL : https://hal.archives-ouvertes.fr/inserm-00623267

R. Schor-bardach, D. C. Alsop, I. Pedrosa, S. A. Solazzo, X. Wang et al., Does arterial spin-labeling MR imaging?measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology, pp.251-731, 2009.

S. Ammari, R. Thiam, C. A. Cuenod, S. Oudard, A. Hernigou et al., Radiological evaluation of response to treatment: Application to metastatic renal cancers receiving anti-angiogenic treatment, Diagnostic and Interventional Imaging, pp.2014-2020
DOI : 10.1016/j.diii.2013.01.019

B. Morgan, A. L. Thomas, J. Drevs, J. Hennig, M. Buchert et al., Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies, Journal of Clinical Oncology, vol.21, issue.21, pp.3955-3964, 2003.
DOI : 10.1200/JCO.2003.08.092

W. J. Edenfield and G. Wilding, Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.12, pp.1371-1377, 2012.

A. A. Van-der-veldt, M. R. Meijerink, A. J. Van-den-eertwegh, A. Bex, G. De-gast et al., Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response, Clinical Cancer Research, vol.14, issue.8, pp.2431-2436, 2008.
DOI : 10.1158/1078-0432.CCR-07-4089

. Motzer, Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials, European Journal of Cancer, vol.50, issue.2, pp.351-358, 2014.

. Boven, Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, Br J Cancer, vol.102, issue.5, pp.803-809, 2010.

J. J. Hiles and J. M. Kolesar, Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma, American Journal of Health-System Pharmacy, vol.65, issue.2, pp.123-154, 2008.
DOI : 10.2146/ajhp060661

E. Frampas, N. Lassau, M. Zappa, M. Vullierme, S. Koscielny et al., Advanced Hepatocellular Carcinoma: Early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results, European Journal of Radiology, vol.82, issue.5, pp.205-211, 2013.
DOI : 10.1016/j.ejrad.2012.12.004

M. Bianchi, M. Sun, and C. Jeldres, Distribution of metastatic sites in renal cell carcinoma: a population-based analysis, Annals of Oncology, vol.23, issue.4, pp.973-980, 2012.
DOI : 10.1093/annonc/mdr362

B. Brufau, C. S. Paño, L. B. Cerqueda, R. S. Villalba, . Izquierdo et al., Metastatic Renal Cell Carcinoma: Radiologic Findings and Assessment of Response to Targeted Antiangiogenic Therapy by Using Multidetector CT, RadioGraphics, vol.33, issue.6, pp.1691-1716, 2013.
DOI : 10.1148/rg.336125110

S. J. Crabb, D. Patsios, E. Sauerbrei, P. M. Ellis, A. Arnold et al., Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.3, pp.404-414, 2009.
DOI : 10.1200/JCO.2008.16.2545